Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19
18 August 2022
| COVID-19: Vaccines
Overview
These are the annexes to WHO interim recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 vaccine against Covid-19. Annexes 1–6 contain tables that summarize the grading of recommendations, assessment, development and evaluations (GRADE). Annexes 7–9 contain the SAGE evidence-to-recommendation framework tables (ETR tables).
GRADE and ETR tables are updated as recommendations are updated.
This document has been updated: Version 18 August 2022.
Related documents:
Interim recommendations for use of the Pfizer–BioNTech BNT162b2 vaccine
Archived version:
- Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19. Version 21 January 2022.
- Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19. Version 19 November 2021.
- Annexes to the recommendations for use of the BNT162b2 vaccine. Version 15 June 2021.
WHO Team
Immunization, Vaccines and Biologicals (IVB),
WHO Headquarters (HQ)
Editors
WHO
Number of pages
75
Reference numbers
WHO Reference Number: WHO-2019-nCoV-vaccines-SAGE-recommendation-BNT162b2-annexes-2022.1
Copyright
